| Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes J Sloan-Lancaster, E Abu-Raddad, J Polzer, JW Miller, JC Scherer, ... Diabetes care 36 (8), 2239-2246, 2013 | 208 | 2013 |
| Mathematical models of diabetes progression A De Gaetano, T Hardy, B Beck, E Abu-Raddad, P Palumbo, ... American Journal of Physiology-Endocrinology and Metabolism 295 (6), E1462-E1479, 2008 | 121 | 2008 |
| A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer MD Galsky, NJ Vogelzang, P Conkling, E Raddad, J Polzer, S Roberson, ... Clinical Cancer Research 20 (13), 3581-3588, 2014 | 114 | 2014 |
| Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes RP Kelly, P Garhyan, E Raddad, H Fu, CN Lim, MJ Prince, JA Pinaire, ... Diabetes, Obesity and Metabolism 17 (4), 414-422, 2015 | 107 | 2015 |
| A decade of innovation in pharmaceutical R&D: the Chorus model PK Owens, E Raddad, JW Miller, JR Stille, KG Olovich, NV Smith, ... Nature Reviews Drug Discovery 14 (1), 17-28, 2015 | 91 | 2015 |
| A phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer M Michael, YJ Bang, YS Park, YK Kang, TM Kim, O Hamid, D Thornton, ... Targeted oncology 12, 463-474, 2017 | 74 | 2017 |
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (Galcanezumab) in healthy volunteers D Monteith, EC Collins, C Vandermeulen, A Van Hecken, E Raddad, ... Frontiers in Pharmacology 8, 740, 2017 | 67 | 2017 |
| Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the … MJ Genin, AB Bueno, J Agejas Francisco, PR Manninen, WP Bocchinfuso, ... Journal of Medicinal Chemistry 58 (24), 9768-9772, 2015 | 50 | 2015 |
| CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial Y Jin, C Smith, D Monteith, R Brown, A Camporeale, TA McNearney, ... Osteoarthritis and Cartilage 26 (12), 1609-1618, 2018 | 44 | 2018 |
| Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small … R Salgia, RW Weaver, M McCleod, JR Stille, SB Yan, S Roberson, ... Investigational new drugs 35, 334-344, 2017 | 38 | 2017 |
| Evaluation of a mathematical model of diabetes progression against observations in the diabetes prevention program T Hardy, E Abu-Raddad, N Porksen, A De Gaetano American Journal of Physiology-Endocrinology and Metabolism 303 (2), E200-E212, 2012 | 28 | 2012 |
| LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase J Sloan-Lancaster, E Raddad, A Flynt, Y Jin, J Voelker, JW Miller Journal of the Renin-Angiotensin-Aldosterone System 18 (3), 1470320317717883, 2017 | 27 | 2017 |
| Occupancy of nociceptin/orphanin FQ peptide receptors by the antagonist LY2940094 in rats and healthy human subjects E Raddad, A Chappell, J Meyer, A Wilson, CE Ruegg, J Tauscher, ... Drug Metabolism and Disposition 44 (9), 1536-1542, 2016 | 25 | 2016 |
| Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587 SB Peng, RD Van Horn, T Yin, RM Brown, WC Roell, VH Obungu, ... Oncotarget 8 (55), 94619, 2017 | 23 | 2017 |
| Safety, pharmacokinetics, and pharmacodynamics of LY2951742: a monoclonal antibody targeting CGRP J De Hoon, D Montieth, S Vermeersch, A Van Hecken, E Abu-Raddad, ... Cephalalgia 33 (S8), 247-248, 2013 | 17 | 2013 |
| Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations S Bihorel, J Fiedler-Kelly, E Ludwig, J Sloan-Lancaster, E Raddad The AAPS journal 16, 1009-1017, 2014 | 14 | 2014 |
| Clinical pharmacokinetics of alamifovir and its metabolites C Chan, E Abu-Raddad, G Golor, H Watanabe, A Sasaki, KP Yeo, D Soon, ... Antimicrobial agents and chemotherapy 49 (5), 1813-1822, 2005 | 14 | 2005 |
| Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose (FBG) and HbA1c in patients with type 2 diabetes mellitus (T2DM) RP Kelly, P Garhyan, EJ Abu-Raddad, H Fu, CN Lim, MJ Prince, ... Diabetes 60, A84-A84, 2011 | 13 | 2011 |
| LY2951742, a monoclonal antibody against CGRP, failed to reduce signs and symptoms of knee osteoarthritis Y Jin, C Smith, D Monteith, R Brown, A Camporeale, T McNearney, ... Osteoarthritis and Cartilage 24, S50, 2016 | 11 | 2016 |
| Catalyst-and Solvent-Free Synthesis of α-Amino Polyfluoroalkylphosphonates from Bis (fluoroalkyl) Phosphonates and Aldimines SN Arbuzova, NK Gusarova, TI Kazantseva, SI Verkhoturova, ... Synthesis 52 (10), 1531-1540, 2020 | 9 | 2020 |
